Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.74 |
| ▸ | GAA | P10253 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 6/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.73 |
| ▸ | HTT | P42858 | 3/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27182315 | 0.96 | MAPT (0.69) | MAPTLMNAGAAMEN1KMT2A | |
| SCHEMBL27182342 | 0.92 | MAPT (0.63) | MAPTLMNAGAAMEN1KMT2A | |
| SCHEMBL2219069 | 0.89 | LMNA (0.76) | MAPTLMNAGAAMEN1KMT2A | |
| SCHEMBL12442514 | 0.88 | LMNA (0.74) | MAPTLMNAGAAMEN1KMT2A | |
| SCHEMBL2217132 | 0.88 | MAPT (0.74) | MAPTLMNAGAAMEN1KMT2A | |
| SCHEMBL15693741 | 0.88 | KMT2A (0.77) | MAPTLMNAGAAMEN1KMT2A | |
| SCHEMBL2215772 | 0.88 | KMT2A (0.80) | MAPTLMNAGAAMEN1KMT2A | |
| SCHEMBL1578589 | 0.87 | KMT2A (0.95) | MAPTLMNAGAAMEN1KMT2A | |
| SCHEMBL1578397 | 0.87 | MAPT (0.69) | MAPTLMNAGAAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1578037 | 0.86 | MAPT (0.72) | MAPTLMNAGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103983627-A | Pyridopyrimidine compounds as anti-tubercular agents | PASTEUR INSTITUT KOREA | 2014-08-13 | — | — | CN | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| CN-102105470-B | Pyridopyrimidine compounds as antitubercular agents | PASTEUR INSTITUT KOREA | 2014-06-04 | — | — | CN | disclosed |
| EP-2730576-A2 | Anti-infective compounds | Institut Pasteur Korea (KR) | 2014-05-14 | — | — | EP | disclosed |
| EP-2730576-A2 | Anti-infective compounds | Institut Pasteur Korea (KR) | 2014-05-14 | — | — | EP | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| CN-102105470-A | Pyridopyrimidine compounds as antitubercular agents | PASTEUR INSTITUT KOREA | 2011-06-22 | — | — | CN | disclosed |
| WO-2010003533-A2 | ANTI-INFECTIVE COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178077-A1 | Anti-infective compounds | RABGGTB, ELANE, SERPINB1 | MAPT 2660/4885LMNA 4132/4885GAA 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.